



Table of contents

Page Number Overview and background Summary Disruptions across service delivery settings and platforms Disruptions to tracer services Service backlog trends Supply chain disruptions Intentional modifications to service delivery and essential public health functions Mitigation strategies and recovery measures Policies, planning and investments Delivery of essential COVID-19 tools Priority needs and technical assistance requirements from WHO 10 In-depth profile: Sexual, reproductive, maternal, newborn, child, and adolescent health In-depth profile: Nutrition services In-depth profile: Care for older people In-depth profile: Immunization In-depth profile: Neglected tropical diseases In-depth profile: Noncommunicable diseases In-depth profile: Mental, neurological, and substance use disorders Key informant details 21

Overview

This profile presents findings from the WHO pulse survey on continuity of essential health services during the COVID-19 pandemic.


|--|

Background


Region	Population	Income Group	GDP (USD per capita)	Life Expectancy (years)	Population 60 and over (%)
AFR	12,952,218	Low income	\$822.3	69.1	5.1%


Survey participation					
Round 1 surveys	Submission Date	Round 3 survey sections	Submission Date	Round 4 survey sections	Submission Date
Essential Health Services	15-Jun-20	Cross-cutting ontinuity of essential health services module	15-Mar-22	Cross-cutting ontinuity of essential health services module	11-Jan-23
Noncommunicable diseases	12-May-20	Sexual, reproductive, maternal, newborn, child and adolescent health	1-Dec-21	Sexual, reproductive, maternal, newborn, child and adolescent health	11-Jan-23
Mental, neurological, and substance use disorders	Did not participate	Nutrition	1-Dec-21	Nutrition	11-Jan-23
		Immunization	1-Dec-21	Immunization	11-Jan-23
Round 2 survey sections		Human immunodeficiency virus and hepatitis	1-Dec-21	Human immunodeficiency virus and hepatitis	11-Jan-23
Cross-cutting ontinuity of essential health services module	17-Feb-21	Tuberculosis	1-Dec-21	Tuberculosis	11-Jan-23
Reproductive, maternal, newborn, child and adolescent health and nutrition	17-Feb-21	Malaria	1-Dec-21	Malaria	11-Jan-23
Immunization	17-Feb-21	Neglected tropical diseases	1-Dec-21	Neglected tropical diseases	11-Jan-23
Human immunodeficiency virus and hepatitis	17-Feb-21	Mental health, neurology and substance use disorders	1-Dec-21	Mental health, neurology and substance use disorders	11-Jan-23
Tuberculosis	17-Feb-21	Care for older people	1-Dec-21	Noncommunicable diseases	11-Jan-23
1alaria	17-Feb-21			Care for older people	11-Jan-23
Neglected tropical diseases	17-Feb-21			Future acute respiratory pandemic preparedness	11-Jan-23
loncommunicable diseases	17-Feb-21				
Mental, neurological, and substance use disorders	17-Feb-21				


Weekly number of new COVID-19 cases and deaths



	Cases	Deaths
Peak	9,776	92
Peak date	2021-07-18	2021-07-11
Latest	0	0
Proportion	0%	0%







ppointments with specialists (outpatient) creening, diagnosis and treatment of ancers creening, diagnosis and treatment of NCDs Not inc Not inc creening, diagnosis and treatment of NCDs Not inc Not inc creening, diagnosis and treatment of NCDs Not inc Creening, diagnosis and treatment of NCDs Not inc Not inc Not inc Not inc Not inc Not inc Creening, diagnosis and treatment of NCDs Not inc Not inc Not inc Not inc Creening, diagnosis and treatment of NCDs Not inc Not inc Not inc Creening, diagnosis and treatment of NCDs Not inc Not inc Creening, diagnosis and treatment of NCDs Not inc Not inc Creening, diagnosis and treatment of NCDs Not inc Not inc Creening, diagnosis and treatment of NCDs Not inc Creening, diagnosis and treatment of NCDs Not inc Not inc Creening, diagnosis and treatment of NCDs Not inc Creening and Creening Not inc Creening and Creening Not inc Creening and Creening Not inc Creening and	ery and essen	Not included in round 2 Tial public health function in round 2 Round 2 (Jan-March 2021) Not included in round 2 Functioning as normal Functioning as normal		Not applicable Not applicable Not applicable Not applicable Not applicable No response And response No response No response The response No response No response No response No response No response No response The response No response No response No response	60% 60% 57% 68% 55% % of countries with disruption 34% 70% 64% 45% 70% 82% 45% 27% 36% Regional comparison (Round 4) Suspended % of	47% 50% 48% 62% 52% on to in-country supply chain system 24% 57% 77% 48% 75% 82% 44% 27% 29% Global comparison (Round 4) Limited of countries 7% 11%
popointments with specialists (outpatient) creening, diagnosis and treatment of ancers creening, diagnosis and treatment of NCDs creening, diagnosis and treatment of NCDs creening, diagnosis and treatment of NCDs chabilitation services Not inc comply chain disruptions: Vaccines Medicines (excluding oxygen) Medical oxygen Laboratory supplies Medical imaging accessories Medical imaging accessories Medical imaging accessories Medical imaging accessories Medical maging accessories Medical imaging accessories Medical maging accessories Medical imaging accessories Medical maging accessories Medical imaging accessories Medical supplies Mot inc Not inc Not inc Not inc Not inc Magina Imary care services Intentional modifications to service deliver supplies Not inc Maginary care services Intentional modifications Imary care services Intentional Imary care services	acluded in round 1	Not included in round 2 Tall public health function of the public heal	Decreased Decreased Decreased No No Not included in round 3 Not or included in round 3 Not or included in round 3 Not included in round 3 Tions Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal	Not applicable Not applicable Not applicable Not applicable No response Functioning as normal	60% 57% 68% 55% % of countries with disruption 34% 70% 64% 45% 70% 82% 45% 27% 36% Regional comparison (Round 4) Suspended % of 11% 16%	50% 48% 62% 52% 51% 57% 77% 48% 75% 82% 44% 27% 29% Clobal comparison (Round 4) Limited Cof countries 79%
creening, diagnosis and treatment of ancers creening, diagnosis and treatment of NCDs creening creening, diagnosis and treatment of NCDs creening cree	acluded in round 1	Not included in round 2 Tial public health function in round 2 Round 2 (Jan-March 2021) Not included in round 2 Functioning as normal	Decreased Decreased No No Not included in round 3 Not or included in round 3 Not or included in round 3 Not included in round 3 Tions Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal	Not applicable Not applicable Not applicable No response And response No response Functioning as normal	57% 68% 55% % of countries with disruption 34% 70% 64% 45% 70% 82% 45% 27% 36% Regional comparison (Round 4) Suspended % of 11% 16%	48% 62% 52% on to in-country supply chain system 24% 57% 77% 48% 75% 82% 44% 27% 29% Clobal comparison (Round 4) Limited of countries 7%
creening, diagnosis and treatment of NCDs creening creeni	acluded in round 1	Not included in round 2 Yes Not included in round 2 Tial public health function of the series of	No Not included in round 3 Not oncluded in round 3 Tions Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal	Not applicable Not applicable No response And response No response Functioning as normal	68% 55% % of countries with disruption 34% 70% 64% 45% 70% 82% 45% 27% 36% Regional comparison (Round 4) Suspended % of 11% 16%	62% 52% on to in-country supply chain system 24% 57% 77% 48% 75% 82% 44% 27% 29% Global comparison (Round 4) Limited of countries 7%
creening, diagnosis and treatment of NCDs chabilitation services Not inc chabilitation services Not inc chapply chain disruptions: Vaccines Medicines (excluding oxygen) Not inc Medicines (excluding oxygen) Not inc Medical oxygen Laboratory supplies Not inc Medical imaging accessories Personal protective equipment Disinfectant and hygiene supplies not inc Not inc Medical imaging accessories Personal protective equipment Colisinfectant and hygiene supplies Not inc Medical imaging accessories Personal protective equipment Colisinfectant and hygiene supplies Not inc Medical imaging accessories Personal protective equipment Colisinfectant and hygiene supplies Not inc Medical supplies Not inc Not in	acluded in round 1	Yes Not included in round 2 Tall public health function of the second	No Not included in round 3 Not oncluded in round 3 Not oncluded in round 3 Not included in round 3 Tions Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal	No No response Functioning as normal	% of countries with disruption 34% 70% 64% 45% 70% 82% 45% 27% 36% Regional comparison (Round 4) Suspended % of countries with disruption Suspended % of countries with disruption Suspended	52% on to in-country supply chain system 24% 57% 77% 48% 75% 82% 44% 27% 29% Global comparison (Round 4) Limited of countries 7%
chabilitation services Not incomply chain disruptions: Vaccines Medicines (excluding oxygen) Medical oxygen Not incomply chain disruptions: Medicines (excluding oxygen) Medical oxygen Not incomply chain disruptions Medical oxygen Not incomply chain disruptions Medical oxygen Medical supplies Medical imaging accessories Mot incomply chain and hygiene supplies Not incomply care accessories Intentional modifications to service delivery platform accessories Intentional modifications to service delivery	acluded in round 1	Yes Not included in round 2 Tall public health function of the second	No Not included in round 3 Not oncluded in round 3 Not oncluded in round 3 Not included in round 3 Tions Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal	No No response Functioning as normal	% of countries with disruption 34% 70% 64% 45% 70% 82% 45% 27% 36% Regional comparison (Round 4) Suspended % of countries with disruption Suspended % of countries with disruption Suspended	52% on to in-country supply chain system 24% 57% 77% 48% 75% 82% 44% 27% 29% Global comparison (Round 4) Limited of countries 7%
Supply chain disruptions: Vaccines Medicines (excluding oxygen) Medical oxygen Not inc. Medical oxygen Not inc. Medical supplies Medical supplies Medical imaging accessories Personal protective equipment Disinfectant and hygiene supplies Intentional modifications to service delivery platform accessories Intentional modifications to	acluded in round 1	Not included in round 2 Tial public health function (Jan-March 2021) Not included in round 2 Functioning as normal Functioning as normal	Not included in round 3 Not oncluded in round 3 Tions Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal	No response Functioning as normal	% of countries with disruption 34% 70% 64% 45% 70% 82% 45% 27% 36% Regional comparison (Round 4) Suspended % of the comparison	24% 57% 77% 48% 75% 82% 44% 27% 29% Clobal comparison (Round 4) Limited Def countries 7%
Vaccines Vaccines Medicines (excluding oxygen) Medical oxygen Medical oxygen Laboratory supplies Medical imaging accessories Personal protective equipment Disinfectant and hygiene supplies Intentional modifications to service deliver trategic changes to service delivery platform accessories patient services Intentional modifications to service delivery platform accessories Intentional modifications to service delivery platform access	acluded in round 1	Not included in round 2 Tial public health function (Jan-March 2021) Not included in round 2 Functioning as normal Functioning as normal	Not included in round 3 Not oncluded in round 3 Tions Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal	No response Very and 4 (Nov 2022-Jan 2023) Functioning as normal	70% 64% 45% 70% 82% 45% 27% 36% Regional comparison (Round 4) Suspended % of	24% 57% 77% 48% 75% 82% 44% 27% 29% Global comparison (Round 4) Limited of countries 7%
Vaccines Vaccines Medicines (excluding oxygen) Medical oxygen Medical oxygen Laboratory supplies Medical imaging accessories Personal protective equipment Disinfectant and hygiene supplies Intentional modifications to service deliver trategic changes to service delivery platform accessories patient services Intentional modifications to service delivery platform accessories Intentional modifications to service delivery platform access	acluded in round 1	Not included in round 2 Tial public health function (Jan-March 2021) Not included in round 2 Functioning as normal Functioning as normal	Not included in round 3 Not oncluded in round 3 Tions Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal	No response Very and 4 (Nov 2022-Jan 2023) Functioning as normal	70% 64% 45% 70% 82% 45% 27% 36% Regional comparison (Round 4) Suspended % of	57% 77% 48% 75% 82% 44% 27% 29% Global comparison (Round 4) Limited of countries 7%
Medicines (excluding oxygen) Medical oxygen Laboratory supplies Medical supplies Medical supplies Medical imaging accessories Personal protective equipment Disinfectant and hygiene supplies Intentional modifications to service deliver platform accessories Intentional modifications to service delivery platform accessories Intentional modifications to serv	acluded in round 1	Not included in round 2 Tial public health function (Jan-March 2021) Not included in round 2 Tunctioning as normal Functioning as normal	Not included in round 3 Tions Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal	No response Functioning as normal Functioning as normal	64% 45% 70% 82% 45% 27% 36% Regional comparison (Round 4) Suspended % 6	77% 48% 75% 82% 44% 27% 29% Global comparison (Round 4) Limited of countries 7%
Medical oxygen Medical oxygen Laboratory supplies Medical supplies Medical imaging accessories Personal protective equipment Disinfectant and hygiene supplies Intentional modifications to service deliver trategic changes to service delivery platform access imary care services Intentional modifications to service deliver trategic changes to service delivery platform access imary care services Intentional modifications to service deliver (Maximary care services Functional modifications to service delivery platform acce (Maximary care services Functional modifications to service delivery platform acce (Maximary care serv	acluded in round 1	Not included in round 2 tial public health function (Jan-March 2021) Not included in round 2 Functioning as normal Functioning as normal	Not included in round 3 Not oncluded in round 3 Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal	No response No response No response No response No response No response Round 4 (Nov 2022-Jan 2023) Functioning as normal	45% 70% 82% 45% 27% 36% Regional comparison (Round 4) Suspended % 6	48% 75% 82% 44% 27% 29% Global comparison (Round 4) Limited of countries 7%
Laboratory supplies Medical supplies Medical imaging accessories Personal protective equipment Disinfectant and hygiene supplies Intentional modifications to service deliver trategic changes to service delivery platform accessories Imaginary care services Intentional modifications to service deliver Imaginary care services Imaginary care service delivery platform access Imaginary care service service delivery platform access Imaginary care service servic	acluded in round 1	Not included in round 2 tial public health function (Jan-March 2021) Not included in round 2 Functioning as normal Functioning as normal	Not included in round 3 Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal	No response No response No response No response No response Round 4 (Nov 2022-Jan 2023) Functioning as normal	70% 82% 45% 27% 36% Regional comparison (Round 4) Suspended % 6	75% 82% 44% 27% 29% Global comparison (Round 4) Limited of countries 7%
Medical imaging accessories Personal protective equipment Disinfectant and hygiene supplies Not incomplete trategic changes to service delivery platform accessories Punctions are services Punctions to service delivery platform accessories Punctions to service delivery platform accessories Punctions to service delivery platform accessories Punctions Punct	acluded in round 1	Not included in round 2 tial public health function Round 2 (Jan-March 2021) Not included in round 2 Functioning as normal Functioning as normal	Not included in round 3 Tions Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal	No response No response No response No response Round 4 (Nov 2022-Jan 2023) Functioning as normal Functioning as normal	82% 45% 27% 36% Regional comparison (Round 4) Suspended % (82% 44% 27% 29% Global comparison (Round 4) Limited of countries 7%
Medical imaging accessories Personal protective equipment Disinfectant and hygiene supplies Intentional modifications to service delivery platform accessories Intentional modifications to service delivery pla	acluded in round 1	Not included in round 2 Not included in round 2 Not included in round 2 tial public health function (Jan-March 2021) Not included in round 2 Functioning as normal Functioning as normal	Not included in round 3 Not included in round 3 Not included in round 3 Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal Functioning as normal	No response No response No response Round 4 (Nov 2022-Jan 2023) Functioning as normal Functioning as normal	45% 27% 36% Regional comparison (Round 4) Suspended % (11% 16%	44% 27% 29% Global comparison (Round 4) Limited of countries 7%
Personal protective equipment Disinfectant and hygiene supplies Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accomp	recluded in round 1 recluded in round 1 lay-Sept 2020) cluded in round 1 tioning as normal tioning as normal	Not included in round 2 Round 2 (Jan-March 2021) Not included in round 2 Functioning as normal Functioning as normal Functioning as normal	Not included in round 3 Ctions Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal Functioning as normal	No response Round 4 (Nov 2022-Jan 2023) Functioning as normal Functioning as normal	27% 36% Regional comparison (Round 4) Suspended % 6	27% 29% Global comparison (Round 4) Limited of countries 7%
Disinfectant and hygiene supplies Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications to service delivery platform accompany care services Intentional modifications function Intentional modifications to service delivery platform accompany care services Intentional modifications function Intentional modifications to service delivery platform accompany care services Intentional modifications function function functions functions functions for health protection functions functions functions for health protection functions functions for health protection functions funct	rery and essent cess Round 1 lay-Sept 2020) Included in round 1 Itioning as normal Itioning as normal	Round 2 (Jan-March 2021) Not included in round 2 Functioning as normal Functioning as normal Functioning as normal	Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal Functioning as normal	Round 4 (Nov 2022-Jan 2023) Functioning as normal Functioning as normal	Regional comparison (Round 4) Suspended % 6	Global comparison (Round 4) Limited of countries
imary care services imary care services utpatient services patient services rehospital emergency care ervices remmunity-based care obile clinics trategic changes to essential public health function (Ma Opulation-based activities for health protection Not incompatible to the compatible of the composition of	Round 1 lay-Sept 2020) Included in round 1 Itioning as normal Itioning as normal	Round 2 (Jan-March 2021) Not included in round 2 Functioning as normal Functioning as normal	Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal	(Nov 2022-Jan 2023) Functioning as normal Functioning as normal	(Round 4) Suspended % 0 11% 16%	(Round 4) Limited of countries 7%
imary care services Interpolation to service delivery platform accompanies to service delivery platform accompanies to services Interpolation to service to service to services Interpolation to service to servi	Round 1 lay-Sept 2020) Included in round 1 Itioning as normal Itioning as normal	Round 2 (Jan-March 2021) Not included in round 2 Functioning as normal Functioning as normal	Round 3 (Nov-Dec 2021) Functioning as normal Functioning as normal	(Nov 2022-Jan 2023) Functioning as normal Functioning as normal	(Round 4) Suspended % 0 11% 16%	(Round 4) Limited of countries 7%
imary care services utpatient services patient services mergency unit services rehospital emergency care revices remmunity-based care obile clinics trategic changes to essential public health functi (Ma	Round 1 lay-Sept 2020) Included in round 1 Itioning as normal Itioning as normal	(Jan-March 2021) Not included in round 2 Functioning as normal Functioning as normal	(Nov-Dec 2021) Functioning as normal Functioning as normal	(Nov 2022-Jan 2023) Functioning as normal Functioning as normal	(Round 4) Suspended % 0 11% 16%	(Round 4) Limited of countries 7%
imary care services Interpolation to services Impatient services	acluded in round 1 tioning as normal tioning as normal	(Jan-March 2021) Not included in round 2 Functioning as normal Functioning as normal	(Nov-Dec 2021) Functioning as normal Functioning as normal	(Nov 2022-Jan 2023) Functioning as normal Functioning as normal	(Round 4) Suspended % 0 11% 16%	(Round 4) Limited of countries 7%
patient services patient services prepatient services prepared unit service	tioning as normal tioning as normal	Functioning as normal Functioning as normal Functioning as normal	Functioning as normal Functioning as normal	Functioning as normal	11% 16%	of countries 7%
patient services patient services prepatient services prepared unit service	tioning as normal tioning as normal	Functioning as normal Functioning as normal Functioning as normal	Functioning as normal Functioning as normal	Functioning as normal	11% 16%	7%
rehospital emergency care ervices remmunity-based care obile clinics trategic changes to essential public health function opulation-based activities for health protection ealth promotion population-based activities Function Not incomparison.	tioning as normal	Functioning as normal Functioning as normal	Functioning as normal			11%
rehospital emergency care ervices remmunity-based care obile clinics trategic changes to essential public health function opulation-based activities for health protection ealth promotion population-based activities Function Not incomparison.	tioning as normal	Functioning as normal Functioning as normal	Functioning as normal			TT 70
rehospital emergency care privices remaining the properties of th	tioning as normal	Functioning as normal		Functioning as normal	4 40 /	
rehospital emergency care ervices Dommunity-based care Dobile clinics Function Mot include the production of the p			Functioning as normal		14%	10%
pommunity-based care pobile clinics Function Function	tioning as normal	Functioning as normal		Functioning as normal	5%	4%
trategic changes to essential public health function (Ma opulation-based activities for health protection ealth promotion population-based activities Not income	Jus Horridi		Functioning as normal	Functioning as normal	22%	11%
trategic changes to essential public health function (Ma opulation-based activities for health protection ealth promotion population-based activities Not income	tioning as normal	Limited	Functioning as normal	Functioning as normal	22%	16%
opulation-based activities for health protection ealth promotion population-based activities Not inc	tioning as normal	Suspended	Functioning as normal	Functioning as normal	24%	20%
opulation-based activities for health protection ealth promotion population-based activities Not inc						
opulation-based activities for health protection ealth promotion population-based activities Not inc	tions and activitie	es				
opulation-based activities for health protection ealth promotion population-based activities Not inc	Round 1	Round 2	Round 3	Round 4	Regional comparison	Global comparison
ealth promotion population-based activities Not inc	lay-Sept 2020)	(Jan-March 2021)	(Nov-Dec 2021)	(Nov 2022-Jan 2023)	(Round 4)	(Round 4)
ealth promotion population-based activities Not inc					Suspended	Limited
	cluded in round 1	Functioning as normal	Functioning as normal	Functioning as normal	29%	of countries 15%
isease prevention population-based activities Not inc	cluded in round 1	Functioning as normal	Functioning as normal	Functioning as normal	11%	11%
	cluded in round 1	Functioning as normal	Functioning as normal	Functioning as normal	17%	13%
urveillance and response Not inc	cluded in round 1	Functioning as normal	Functioning as normal	Functioning as normal	19%	10%
	icluded in round 1	Functioning as normal	Functioning as normal	Functioning as normal	16%	12%
ommunications and social mobilization activities						
r health	cluded in round 1	Functioning as normal	Functioning as normal	Functioning as normal	300/	
ublic health research Not inc		Functioning as neget			20%	12%
	cluded in round 1	Functioning as normal	Functioning as normal	Functioning as normal	31%	25%
overnment staff responsible for EHS elivery have been reassigned/deployed to Not inc	Round 1 lay-Sept 2020)	Round 2 (Jan-March 2021)	Functioning as normal Round 3 (Nov-Dec 2021)	Functioning as normal Round 4 (Nov 2022-Jan 2023)	31%	


	measures Pound 1	Dound 2	Down d 2	Dound 4	Degional comparison	Global comparison
Service delivery modifications	Round 1 (May-Sept 2020)	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4)	Global comparison (Round 4)
					% of countries using stra	ategy (with or without integration)
Expansion of facility hours	Not included in round 1	×	×	Used but not integrated into routine service delivery	50%	52%
Provision of home-based care where appropriate	Not included in round 1	×	✓	Used but not integrated into routine service delivery	71%	69%
Telemedicine deployment to replace in-person consults	Not included in round 1	×	×	Used but not integrated into routine service delivery	44%	66%
Use of self-care interventions where appropriate	Not included in round 1	×	×	Used but not integrated into routine service delivery	74%	65%
Catch-up campaigns for missed appointments	Not included in round 1	×	×	Used but not integrated into routine service delivery	71%	53%
Integration of several services into single visit	Not included in round 1	×	×	Used but not integrated into routine service delivery	44%	42%
Redirection of patients to alternate care sites/reorientation of referral pathways	No response	×	✓	Used but not integrated into routine service delivery	62%	58%
Health worker capacities and training					% of countries using stra	ategy (with or without integration)
Redistribution of health worker tasks and optimization of roles	Not applicable	×	✓	Used but not integrated into routine service delivery	65%	72%
Rapid training mechanisms and job aids for key capacities and newly distributed tasks and roles	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	76%	80%
Recruitment of additional staff	No response	×	√	Used but not integrated into routine service delivery	74%	71%
Provision of mental health care and psychosocial support to health workers	Not included in round 1	Not included in round 2	✓	Used but not integrated into routine service delivery	74%	63%
Establishment of pathways for accelerated training and early certification of medical, nursing and other key staff	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	32%	40%
Paid sick leave, overtime pay, and/or hazard pay	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	47%	55%
Access to medicines and health products					% of countries using stra	ategy (with or without integration)
Novel approaches to renewing prescriptions and dispensing medications	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	50%	56%
Adaption of supply chain logistics and management processes	Not applicable	×	×	Used but not integrated into routine service delivery	65%	71%
Procurement of surge commodities (e.g. PPE, oxygen)	Not included in round 1	Not included in round 2	✓	Used but not integrated into routine service delivery	79%	75%
Community engagement and risk communica	tion strategies				% of countries using stra	ategy (with or without integration)
Community communications	Not applicable	✓	√	Used but not integrated into routine service delivery	88%	89%
Jse of proactive governmental strategies to reach vulnerable groups	Not included in round 1	×	✓	Used but not integrated into routine service delivery	44%	63%
Use of existing networks or organizations (e.g. NGOs) to reach vulnerable groups	Not included in round 1	✓	✓	Used but not integrated into routine service delivery	82%	77%
Health financing strategies					% of countries using stra	ategy (with or without integration)
Removal of user fees or provision of subsidies for fees at point of use	Not applicable	×	No response	Used but not integrated into routine service delivery	32%	41%
Provision of cash transfers for vulnerable copulations to access care	Not included in round 1	Not included in round 2	No response	Used but not integrated into routine service delivery	38%	29%
Agreements with private health facilities to deliver essential health services supported through public funds	Not included in round 1	Not included in round 2	No response	Used but not integrated into routine service delivery	53%	48%
					% of countries using stra	ategy (with or without integration)
approaches	Not included in round 1	Not included in round 2	Not included in round 3	Used but not integrated into routine service delivery	62%	68%
Improving the quality of care in essential health	Not included in round 1 Not included in round 1	Not included in round 2 Not included in round 2	Not included in round 3 Not included in round 3		76%	68%
Systematic use of quality improvement approaches Improving patient flow in health facilities Improving the quality of care in essential health services delivered to patients Providing training and supportive supervision of the workforce in quality improvement				Used but not integrated into		

Policies, planning and investments						
Policies and plans	Round 1 (May-Sept 2020)	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4)	Global comparison (Round 4)
					% of countries	responding yes
Government has defined EHS to be maintained during COVID-19	Yes	Yes	Yes, developed	Yes, developed and revised in last year	50%	59%
Country developed or revised a health system recovery plan to strengthen health service resilience and preparedness for future public health emergencies	Not included in round 1	Not included in round 2	Not yet, but planning to develop	Not yet, but planning to develop	39%	44%
Plan has been budgeted	Not included in round 1	Not included in round 2	Not included in round 3	No response	92%	92%
Implementation of plan has started	Not included in round 1	Not included in round 2	Not included in round 3	No response	83%	95%
Implentation hasn't started because:						
Focus is still currently on pandemic response	Not included in round 1	Not included in round 2	Not included in round 3	No response	Sample size too small to display.	Sample size too small to displa
Focus is currently on socio-economic recovery	Not included in round 1	Not included in round 2	Not included in round 3	No response	Sample size too small to display	Sample size too small to displa
Limited resources	Not included in round 1	Not included in round 2	Not included in round 3	No response	Sample size too small to display	Sample size too small to displa
No designated authority/platform/mechanism to coordinate implementation	Not included in round 1	Not included in round 2	Not included in round 3	No response	Sample size too small to display	Sample size too small to displa
A focused review was used to inform recovery plan	Not included in round 1	Not included in round 2	Not included in round 3	No response	82%	94%
hematic areas that have been identified as central	to ongoing recovery effort:				% of countries	responding yes
Primary Care	Not included in round 1	Not included in round 2	Not included in round 3	✓	89%	89%
Emergency risk management including preparedness	Not included in round 1	Not included in round 2	Not included in round 3	✓	95%	84%
Other essential public health functions	Not included in round 1	Not included in round 2	Not included in round 3	✓	42%	62%
Continuity of essential health services across health programmes and conditions	Not included in round 1	Not included in round 2	Not included in round 3	✓	89%	83%
Whole of government / multisectoral engagement	Not included in round 1	Not included in round 2	Not included in round 3	✓	58%	57%
Community engagement	Not included in round 1	Not included in round 2	Not included in round 3	✓	92%	75%
Vulnerable and marginalized populations	Not included in round 1	Not included in round 2	Not included in round 3	✓	68%	65%
Quality of care	Not included in round 1	Not included in round 2	Not included in round 3	✓	76%	63%
None	Not included in round 1	Not included in round 2	Not included in round 3		0%	2%
Country made additional government funding and investments	Round 1 (May-Sept 2020)	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4) % of countries	Global comparison (Round 4) responding yes
o maintain EHS during COVID-19	✓	×	✓	×	76%	83%
o cover reductions in loss of revenue	Not included in round 1	Not included in round 2	Not included in round 3	×	28%	56%
For longer-term recovery and/or health service esilience and preparedness	Not included in round 1	Not included in round 2	✓	×	58%	74%
Sub-areas where investments have been made					% of countries	responding yes
New facility infrastructure	Not included in round 1	Not included in round 2	✓	N/A	78%	81%
Digital health technologies and infrastructure	Not included in round 1	Not included in round 2	✓	N/A	67%	87%
Health workforce capacity strengthening	Not included in round 1	Not included in round 2	✓	N/A	100%	95%
Access to medicines, supplies and other health products	Not included in round 1	Not included in round 2	✓	N/A	89%	86%
Health information systems	Not included in round 1	Not included in round 2	✓	N/A	83%	80%

Country received additional external	D	Downd 2	Dound 2	Dound 4	% of countries	responding yes
funding to support health system recovery efforts from:	Round 1 (May-Sept 2020)	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)		
None	Not included in round 1	Not included in round 2	Not included in round 3		0%	15%
WHO	Not included in round 1	Not included in round 2	Not included in round 3	-	87%	78%
Other UN agencies and multilateral development banks	Not included in round 1	Not included in round 2	Not included in round 3	-	87%	75%
Bilateral development partners	Not included in round 1	Not included in round 2	Not included in round 3	-	87%	64%
International non-governmental organizations (not for profit)	Not included in round 1	Not included in round 2	Not included in round 3	✓	61%	58%
National non-governmental organizations (not for profit)	Not included in round 1	Not included in round 2	Not included in round 3	-	37%	41%
International private organizations (for profit)	Not included in round 1	Not included in round 2	Not included in round 3		32%	30%
National private organizations (for profit)	Not included in round 1	Not included in round 2	Not included in round 3		26% % of countries	27% responding yes
There is a designated national authority with clear responsibility for coordinating health system recovery efforts within the health sector and/or across other sectors	Not included in round 1	Not included in round 2	Not included in round 3		74%	78%
Information tracking	Round 1 (May-Sept 2020)	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4) % of countries	Global comparison (Round 4) responding yes
Regularly monitoring the continuity of EHS during COVID-19	Not included in round 1	Yes	Yes	Yes	86%	88%
If yes, does it include monitoring mitigation or recovery strategies	Not included in round 1	Yes	Yes	Yes	86%	82%
If yes, does it include monitoring of the long- term effects of essential health service disruptions	Not included in round 1	Not included in round 2	Yes	Yes	81%	80%
If yes, does it include monitoring of barriers to accessing essential health services	Not included in round 1	Not included in round 2	Not included in round 3	Yes	93%	85%
If yes, does it include monitoring of changes in care-seeking behaviour	Not included in round 1	Not included in round 2	Not included in round 3	Yes	93%	83%
Focused review and documentation of the current situation and the impact of the pandemic in order to inform recovery planning	Not included in round 1	Not included in round 2	Not included in round 3	Yes	79%	76%
Existence of team dedicated to tracking and					% of countries	responding yes
addressing the infodemic and health misinformation during COVID-19	Not included in round 1	Yes, within Ministry of Health or equivalent	Yes, within Ministry of Health or equivalent	Yes, within Ministry of Health or equivalent	95%	90%
Collecting or collating data on comorbidities in COVID-19 patients	Not included in round 1	Yes	Yes	Yes	97%	94%
Collecting or collating patient-level data on post-COVID-19 condition and its sequelae	Not included in round 1	Not included in round 2	Yes	No	52%	57%
Active, multi-source social listening mechanism in place to inform decision-makin	Not included in round 1	Not included in round 2	Not included in round 3	Yes	71%	63%
Produced one or more qualitative or quantitative analysis of health inequities during the COVID-19 pandemic	Not included in round 1	Not included in round 2	Yes	Yes	65%	66%
Capacities for potential COVID-19 surge	Round 1 (May-Sept 2020)	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4) % of countries	Global comparison (Round 4) responding yes
Current curge capacity assessed	Not included in round 1	Not included in round 2	Not included in round 3	No, but in process of completion	44%	42%
Priority health capacity strengthening areas	for potential COVID-19 s	urge (top 3)			% of countries	responding yes
Multisectoral coordination, governance and financing	Not included in round 1	Not included in round 2	Not included in round 3		55%	64%
Surveillance, laboratories and diagnostics	Not included in round 1	Not included in round 2	Not included in round 3	✓	74%	60%
Risk communication and community engagement	Not included in round 1	Not included in round 2	Not included in round 3	-	61%	54%
Managing essential health services and systems	Not included in round 1	Not included in round 2	Not included in round 3	-	18%	33%
Points of entry, international travel and transport, and mass gatherings	Not included in round 1	Not included in round 2	Not included in round 3	-	42%	26%
Protection of health workforce	Not included in round 1	Not included in round 2	Not included in round 3	-	24%	27 %
Infection prevention and control	Not included in round 1	Not included in round 2	Not included in round 3	-	21%	17%
Operational support, logistics and supply chains	Not included in round 1	Not included in round 2	Not included in round 3	✓	18%	17%
Research and development	Not included in round 1	Not included in round 2	Not included in round 3	-	8%	14%
Case management and clinical operations	Not included in round 1	Not included in round 2	Not included in round 3	✓	24%	14%

	Round 1 (May-Sept 2020)	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4)	Global comparison (Round 4)
cities that were strengthened or institut ID-19 public health emergency or disast		·19 pandemic that have be	en leveraged in response	for any other non-	% of cour	ntries responding yes
ot applicable/no other public health nergencies or disasters	Not included in round 1	Not included in round 2	Not included in round 3		8%	15%
ultisectoral coordination, governance and nancing	Not included in round 1	Not included in round 2	Not included in round 3	✓	86%	76%
sk communication, community engagement and infodemic management	Not included in round 1	Not included in round 2	Not included in round 3	✓	94%	83%
urveillance, laboratories and diagnostics	Not included in round 1	Not included in round 2	Not included in round 3	✓	94%	90%
oints of entry, international travel and ansport, and mass gatherings	Not included in round 1	Not included in round 2	Not included in round 3	✓	83%	72%
otection of health workforce	Not included in round 1	Not included in round 2	Not included in round 3	✓	71%	69%
ase management, clinical operations	Not included in round 1	Not included in round 2	Not included in round 3	✓	77%	66%
fection prevention and control	Not included in round 1	Not included in round 2	Not included in round 3	✓	89%	82%
perational support, logistics and supply chains	Not included in round 1	Not included in round 2	Not included in round 3	✓	83%	78%
anaging essential health services and systems	Not included in round 1	Not included in round 2	Not included in round 3	✓	74%	71%
esearch and development	Not included in round 1	Not included in round 2	Not included in round 3	✓	51%	47%
one	Not included in round 1	Not included in round 2	Not included in round 3		0%	0%
ere is a national multisectoral committee for ure respiratory pathogen pandemic eparedness untry has respiratory pathogen preparedness		Not included in round 2	Not included in round 3	Yes (or being established)	73%	74%
n ree priority health capacity strengthening areas		Not included in round 2	Not included in round 3	No but planning to dovolon		
Multisectoral coordination, governance			Troc included in round 5	No, but planning to develop one	55% % of cour	68% otries responding ves
		Not included in round 2	Not included in round 3			68% htries responding yes 66%
and financing Risk communication and community		Not included in round 2 Not included in round 2		one	% of cou	ntries responding yes
and financing			Not included in round 3	one ×	73%	ntries responding yes 66%
and financing Risk communication and community engagement		Not included in round 2	Not included in round 3 Not included in round 3	one ×	73% 34%	ntries responding yes 66% 35%
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce		Not included in round 2 Not included in round 2	Not included in round 3 Not included in round 3 Not included in round 3	one × ×	73% 34% 32% 5%	ntries responding yes 66% 35% 73%
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control		Not included in round 2	Not included in round 3	one × × × ×	73% 34% 32% 5% 32%	17% 24%
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and		Not included in round 2	Not included in round 3	<pre> x x x x x x x x x x x x x</pre>	73% 34% 83% 5% 5% 15%	15% htries responding yes 66% 35% 73% 23% 17% 15%
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control Operational support, logistics and supply chains		Not included in round 2	Not included in round 3	<pre></pre>	73% 34% 32% 5% 15% 5%	66% 35% 73% 23% 17% 24% 15% 17%
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control Operational support, logistics and supply chains Managing essential health services and systems Planning for pandemic product deployment (vaccines, therapeutics and other devices)		Not included in round 2	Not included in round 3	one	73% 34% 83% 32% 5% 15% 5% 5%	66% 35% 73% 23% 17% 24% 15% 4% 4%
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control Operational support, logistics and supply chains Managing essential health services and systems Planning for pandemic product deployment (vaccines, therapeutics and other devices) Research and development e following ministries/agencies are engaged in		Not included in round 2	Not included in round 3	<pre></pre>	73% 34% 83% 5% 5% 5% 5% 15%	66% 35% 73% 23% 17% 24% 15% 17% 14%
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control Operational support, logistics and supply chains Managing essential health services and systems Planning for pandemic product deployment (vaccines, therapeutics and other devices) Research and development of following ministries/agencies are engaged in ure respiratory pathogen pandemic eparedness		Not included in round 2	Not included in round 3	one	73% 34% 83% 5% 5% 15% 5% % of cour	66% 35% 73% 23% 17% 24% 15% 17% 4% 14% httries responding yes
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control Operational support, logistics and supply chains Managing essential health services and systems Planning for pandemic product deployment (vaccines, therapeutics and other devices) Research and development e following ministries/agencies are engaged in are respiratory pathogen pandemic paredness National legislative body, office of head of state		Not included in round 2	Not included in round 3	one	73% 34% 83% 32% 5% 5% 15% 5% 71%	66% 35% 73% 23% 17% 24% 15% 17% 4% 14% htries responding yes
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control Operational support, logistics and supply chains Managing essential health services and systems Planning for pandemic product deployment (vaccines, therapeutics and other devices) Research and development e following ministries/agencies are engaged in are respiratory pathogen pandemic paredness National legislative body, office of head of state Finance		Not included in round 2	Not included in round 3	one	73% 34% 83% 32% 5% 5% 5% 5% 71% 83%	66% 35% 73% 23% 17% 15% 17% 4% 14% httries responding yes
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control Operational support, logistics and supply chains Managing essential health services and systems Planning for pandemic product deployment (vaccines, therapeutics and other devices) Research and development e following ministries/agencies are engaged in are respiratory pathogen pandemic paredness National legislative body, office of head of state		Not included in round 2	Not included in round 3	one	73% 34% 83% 32% 5% 5% 15% 5% 71%	66% 35% 73% 23% 17% 24% 15% 17% 4% 14% htries responding yes
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control Operational support, logistics and supply chains Managing essential health services and systems Planning for pandemic product deployment (vaccines, therapeutics and other devices) Research and development e following ministries/agencies are engaged in are respiratory pathogen pandemic paredness National legislative body, office of head of state Finance Disaster risk management		Not included in round 2	Not included in round 3	one	73% 34% 83% 32% 5% 5% 5% 5% 71% 83% 85%	66% 35% 73% 23% 17% 24% 15% 17% 4% 14% ontries responding yes
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control Operational support, logistics and supply chains Managing essential health services and systems Planning for pandemic product deployment (vaccines, therapeutics and other devices) Research and development e following ministries/agencies are engaged in ure respiratory pathogen pandemic paredness National legislative body, office of head of state Finance Disaster risk management Home affairs, interior affairs		Not included in round 2	Not included in round 3	one	73% 34% 83% 32% 5% 32% 15% 5% 71% 83% 85% 63%	66% 35% 73% 23% 17% 24% 15% 17% 4% 16% 66% 68% 77% 59%
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control Operational support, logistics and supply chains Managing essential health services and systems Planning for pandemic product deployment (vaccines, therapeutics and other devices) Research and development e following ministries/agencies are engaged in ure respiratory pathogen pandemic eparedness National legislative body, office of head of state Finance Disaster risk management Home affairs, interior affairs Commerce, trade		Not included in round 2	Not included in round 3	one	73% 34% 83% 32% 5% 5% 5% 5% 71% 83% 85% 63% 46%	66% 35% 73% 23% 17% 24% 15% 17% 4% 14% 14% 14% 17% 39% 39%
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control Operational support, logistics and supply chains Managing essential health services and systems Planning for pandemic product deployment (vaccines, therapeutics and other devices) Research and development e following ministries/agencies are engaged in ure respiratory pathogen pandemic paredness National legislative body, office of head of state Finance Disaster risk management Home affairs, interior affairs Commerce, trade Defense, security forces		Not included in round 2	Not included in round 3	one	73% 34% 83% 32% 5% 5% 5% 5% 71% 83% 85% 63% 46% 78%	66% 35% 73% 23% 17% 24% 15% 17% 4% 14% 66% 68% 77% 59% 39% 68%
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control Operational support, logistics and supply chains Managing essential health services and systems Planning for pandemic product deployment (vaccines, therapeutics and other devices) Research and development efollowing ministries/agencies are engaged in the respiratory pathogen pandemic eparedness National legislative body, office of head of state Finance Disaster risk management Home affairs, interior affairs Commerce, trade Defense, security forces Labour, social welfare		Not included in round 2	Not included in round 3	one	73% 34% 83% 32% 5% 5% 15% 5% 71% 83% 85% 63% 46% 78% 49%	66% 35% 73% 23% 17% 24% 15% 17% 4% 14% 66% 68% 77% 59% 39% 68% 45%
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control Operational support, logistics and supply chains Managing essential health services and systems Planning for pandemic product deployment (vaccines, therapeutics and other devices) Research and development e following ministries/agencies are engaged in ure respiratory pathogen pandemic eparedness National legislative body, office of head of state Finance Disaster risk management Home affairs, interior affairs Commerce, trade Defense, security forces Labour, social welfare Public works and services		Not included in round 2	Not included in round 3	one	73% 34% 83% 32% 5% 32% 15% 5% 15% % of coun 71% 83% 85% 63% 46% 78% 49% 39%	66% 35% 73% 23% 17% 24% 15% 17% 4% 14% 14% 14% 15% 39% 68% 45% 39%
and financing Risk communication and community engagement Surveillance, laboratories and diagnostics Points of entry, international travel and transport, and mass gatherings Protection of health workforce Case management, clinical operations, and infection prevention and control Operational support, logistics and supply chains Managing essential health services and systems Planning for pandemic product deployment (vaccines, therapeutics and other devices) Research and development following ministries/agencies are engaged in the respiratory pathogen pandemic paredness National legislative body, office of head of state Finance Disaster risk management Home affairs, interior affairs Commerce, trade Defense, security forces Labour, social welfare Public works and services Information and communication		Not included in round 2 Not included in round 2	Not included in round 3 Not included in round 3	one	73% 34% 83% 32% 5% 5% 5% 5% 5% 6% 6% 46% 78% 49% 39% 90%	66% 35% 73% 23% 17% 24% 15% 17% 4% 14% 14% 14% 15% 66% 68% 77% 59% 39% 68% 45% 39% 71%

Top three bottlenecks for potential scale up						% of countries responding yes
Lack of funding	Not included in round 1	Not included in round 2	✓	No response	64%	68%
Health workforce challenges	Not included in round 1	Not included in round 2	✓	No response	58%	80%
Shortages in laboratory supplies and equipment	Not included in round 1	Not included in round 2	✓	No response	58%	56%
Lack of distribution capacity	Not included in round 1	Not included in round 2		No response	17%	10%
Lack of clear strategy, guidance or protocols	Not included in round 1	Not included in round 2		No response	14 %	13%
Lack of data/information	Not included in round 1	Not included in round 2		No response	8 %	23%
Demand-side challenges	Not included in round 1	Not included in round 2	-	No response	19%	30%
Top three technical assistance or support inte	erventions needed to addres	ss bottlenecks				% of countries responding yes
Financial planning support	Not included in round 1	Not included in round 2	✓	No response	58%	59%
Health worker recruitment, retention and training	Not included in round 1	Not included in round 2	✓	No response	56%	76%
Operational guidance and protocols for supply chain management	Not included in round 1	Not included in round 2	-	No response	19%	22%
Surge procurement of COVID-19 laboratory supplies and equipment	Not included in round 1	Not included in round 2	✓	No response	47%	37%
Guidance on developing national policies, strategies, or plans for scale up	Not included in round 1	Not included in round 2	-	No response	25%	26%
Rapid tools or guidance to assess and monitor gaps and health system absorption capacities	Not included in round 1	Not included in round 2	-	No response	17%	33%
Risk communication and community engagement	Not included in round 1	Not included in round 2	_	No response	25%	27%
on accyles				140 response		
COVID-19 case management	Round 1 (May-Sept 2020)	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun	mparison Global compariso
COVID-19 case management		Round 2	Round 3	Round 4	Regional co	mparison Global compariso
COVID-19 case management Top three bottlenecks for potential scale up		Round 2	Round 3	Round 4	Regional co	mparison Global comparison d 4) (Round 4)
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges	(May-Sept 2020) Not included in round 1 Not included in round 1	Round 2 (Jan-March 2021) Not included in round 2 Not included in round 2	Round 3	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun	mparison d 4) Global compariso (Round 4) % of countries responding yes 57% 80%
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges Shortages in COVID-19 therapeutics and equipment	(May-Sept 2020) Not included in round 1 Not included in round 1 Not included in round 1	Round 2 (Jan-March 2021) Not included in round 2 Not included in round 2 Not included in round 2	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun 54% 86% 46%	mparison d 4) Global comparison (Round 4) % of countries responding yes 57% 80% 39%
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges Shortages in COVID-19 therapeutics and equipment Lack of distribution capacity	(May-Sept 2020) Not included in round 1	Round 2 (Jan-March 2021) Not included in round 2	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun 54% 86% 46% 19%	mparison (Round 4) % of countries responding yes 57% 80% 17%
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges Shortages in COVID-19 therapeutics and equipment Lack of distribution capacity Lack of facility infrastructure	(May-Sept 2020) Not included in round 1 Not included in round 1 Not included in round 1	Round 2 (Jan-March 2021) Not included in round 2 Not included in round 2 Not included in round 2	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun 54% 86% 46%	mparison d 4) Global comparison (Round 4) % of countries responding yes 57% 80% 39%
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges Shortages in COVID-19 therapeutics and equipment Lack of distribution capacity Lack of facility infrastructure Lack of clear strategy, guidance or protocols	(May-Sept 2020) Not included in round 1	Round 2 (Jan-March 2021) Not included in round 2	Round 3 (Nov-Dec 2021) Not included in round 3	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun 54% 86% 46% 19% 41% 14%	mparison (Round 4) % of countries responding yes 57% 80% 17% 29% 12%
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges Shortages in COVID-19 therapeutics and equipment Lack of distribution capacity Lack of facility infrastructure Lack of clear strategy, guidance or protocols Lack of data/information	Not included in round 1	Round 2 (Jan-March 2021) Not included in round 2	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun 54% 86% 46% 19% 41% 14% 16%	mparison (Round 4) % of countries responding yes 57% 80% 17% 29% 12% 17%
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges Shortages in COVID-19 therapeutics and equipment Lack of distribution capacity Lack of facility infrastructure Lack of clear strategy, guidance or protocols Lack of data/information	Not included in round 1	Round 2 (Jan-March 2021) Not included in round 2	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun 54% 86% 46% 19% 41% 14%	mparison (Round 4) % of countries responding yes 57% 80% 17% 29% 12%
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges Shortages in COVID-19 therapeutics and equipment Lack of distribution capacity Lack of facility infrastructure Lack of clear strategy, guidance or protocols Lack of data/information Demand-side challenges	Not included in round 1	Round 2 (Jan-March 2021) Not included in round 2	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun 54% 86% 46% 19% 41% 14% 16%	mparison (Round 4) % of countries responding yes 57% 80% 17% 29% 12% 17%
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges Shortages in COVID-19 therapeutics and equipment Lack of distribution capacity Lack of facility infrastructure Lack of clear strategy, guidance or protocols Lack of data/information Demand-side challenges Top three technical assistance or support inte	Not included in round 1	Round 2 (Jan-March 2021) Not included in round 2	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun 54% 86% 46% 19% 41% 14% 16%	### Global comparison (Round 4) % of countries responding yes 57% 80% 17% 29% 12% 17% 14%
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges Shortages in COVID-19 therapeutics and equipment Lack of distribution capacity Lack of facility infrastructure Lack of clear strategy, guidance or protocols Lack of data/information Demand-side challenges Top three technical assistance or support inte Financial planning support	(May-Sept 2020) Not included in round 1 erventions needed to address	Round 2 (Jan-March 2021) Not included in round 2 Solution of the state of th	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun 54% 86% 46% 19% 41% 14% 88%	mparison (Round 4) % of countries responding yes 57% 80% 17% 29% 12% 14% % of countries responding yes
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges Shortages in COVID-19 therapeutics and equipment Lack of distribution capacity Lack of facility infrastructure Lack of clear strategy, guidance or protocols Lack of data/information Demand-side challenges Top three technical assistance or support inte Financial planning support Health worker recruitment, retention and training Operational guidance and protocols for supply	Not included in round 1	Round 2 (Jan-March 2021) Not included in round 2	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun 54% 86% 46% 41% 14% 16% 8%	mparison (Round 4) % of countries responding yes 57% 80% 17% 29% 12% 14% % of countries responding yes
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges Shortages in COVID-19 therapeutics and equipment Lack of distribution capacity Lack of facility infrastructure Lack of clear strategy, guidance or protocols Lack of data/information Demand-side challenges Top three technical assistance or support inte Financial planning support Health worker recruitment, retention and training Operational guidance and protocols for supply chain management Surge procurement of COVID-19 related	Not included in round 1 Prventions needed to address to include in round 1 Not included in round 1	Round 2 (Jan-March 2021) Not included in round 2	Round 3 (Nov-Dec 2021) Not included in round 3	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun 54% 86% 46% 19% 41% 14% 16% 8% 54% 81%	mparison (Round 4) % of countries responding yes 57% 80% 17% 29% 12% 14% % of countries responding yes
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges Shortages in COVID-19 therapeutics and equipment Lack of distribution capacity Lack of facility infrastructure Lack of clear strategy, guidance or protocols Lack of data/information Demand-side challenges Top three technical assistance or support inte Financial planning support Health worker recruitment, retention and training Operational guidance and protocols for supply chain management Surge procurement of COVID-19 related therapeutics and equipment	Not included in round 1	Round 2 (Jan-March 2021) Not included in round 2	Round 3 (Nov-Dec 2021) Not included in round 3	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun 54% 86% 46% 19% 41% 14% 16% 8% 81% 22%	mparison d 4) % of countries responding yes 57% 80% 39% 17% 29% 12% 14% % of countries responding yes
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges Shortages in COVID-19 therapeutics and equipment Lack of distribution capacity Lack of facility infrastructure Lack of clear strategy, guidance or protocols Lack of data/information Demand-side challenges Top three technical assistance or support inte Financial planning support Health worker recruitment, retention and training Operational guidance and protocols for supply chain management Surge procurement of COVID-19 related therapeutics and equipment Additional physical infrastructure Guidance on developing national policies, strategies, or plans for scale up	Not included in round 1 Not included in round 1	Round 2 (Jan-March 2021) Not included in round 2	Round 3 (Nov-Dec 2021) / / Not included in round 3 - - - - - - - - - - - - -	Round 4 (Nov 2022-Jan 2023)	Regional co (Round	### Global comparison (Round 4) % of countries responding yes 57% 80% 39% 17% 29% 12% 14% % of countries responding yes 60% 80% 20% 33% 33%
COVID-19 case management Top three bottlenecks for potential scale up Lack of funding Health workforce challenges Shortages in COVID-19 therapeutics and equipment Lack of distribution capacity Lack of facility infrastructure Lack of clear strategy, guidance or protocols Lack of data/information Demand-side challenges Top three technical assistance or support inte Financial planning support Health worker recruitment, retention and training Operational guidance and protocols for supply chain management Surge procurement of COVID-19 related therapeutics and equipment Additional physical infrastructure Guidance on developing national policies,	Not included in round 1 Not included in round 1	Round 2 (Jan-March 2021) Not included in round 2	Round 3 (Nov-Dec 2021) V Not included in round 3 V Not included in round 3 Not included in round 3	Round 4 (Nov 2022-Jan 2023)	Regional co (Roun 54% 86% 46% 19% 41% 14% 22% 35% 41%	### Global comparison (Round 4) % of countries responding yes 57% 80% 39% 17% 29% 12% 14% % of countries responding yes 60% 80% 33%




ritigation strategies and recovery measu	res for sexual and reprod	uctive health services				
Communication and information	Round 1 (May-Sept 2020)	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4)	Global comparison (Round 4)
					% of countries using strateg	y (with or without integration)
of access SRH services	Not included in round 1	Not included in round 2	✓	Used but not integrated into routine service delivery	76%	73%
Providing information to public about accurate and up-to-date educational materials on COVID-9 and SRH	Not included in round 1	Not included in round 2	✓	Used but not integrated into routine service delivery	94%	80%
nforming and alerting all service providers about ne heightened risk of domestic violence	Not included in round 1	Not included in round 2	×	Not used	76%	68%
ccess					% of countries using strateg	y (with or without integration)
ncreasing availability of contraceptive methods and condoms that do not require direct apervision of health workers	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	79%	61%
nhancing identification and services for gender- ased violence against women survivors	Not included in round 1	Not included in round 2	✓	Used but not integrated into routine service delivery	73%	59%
Iternative or adaptive measures					% of countries using strateg	y (with or without integration)
Relaxing requirements for prescriptions of SRH ommodities	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	42%	33%
Offering noninvasive medical methods for nanaging safe abortion	Not included in round 1	Not included in round 2	×	Not used	36%	28%
Vaiving restrictions to accessing SRH services	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	30%	28%
roviding multi-month supplies of SRH ommodities	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	88%	62%
sing hotlines and/or telemedicine to minimize acility visits and provider-client contacts	Not included in round 1	Not included in round 2	No response	Used but not integrated into routine service delivery	56%	56%
djusting forecasting for SRH commodities and upplies	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	85%	59%
educing the cost of SRH services	Not included in round 1	Not included in round 2	×	Not used	52%	39%
mplement task shifting/sharing for essential SRH ervices	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	76%	45%
litigation strategies and recovery measu	res for maternal and new	born health services				
Communication and information					% of countries using strateg	y (with or without integration)
nforming the community where, when and how access MNH services	Not included in round 1	Not included in round 2	✓	Used but not integrated into routine service delivery	88%	73%
romoting childbirth in health facilities respective of COVID-19	Not included in round 1	Not included in round 2	✓	Used but not integrated into routine service delivery	94%	80%
nforming families and caregivers on how to cope with stress and sustain a nurturing environment thome	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	76%	71%
nforming MNH CHWs on IPC measures	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	91%	77%
ccess						
cheduling of ANC visits in advance	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	62%	66%
scheduling of PNC visits in advance	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	56%	65%
lodifying (temporarily) MNH referral system	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	71%	59%
Iternative or adaptive measures	Round 1 (May-Sept 2020)	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4)	Global comparisor (Round 4)
					% of countries using strateg	y (with or without integration)
ffering multi-month prescriptions, micronutrient upplements, etc. during ANC or PNC	Not included in round 1	Not included in round 2	×	Used but not integrated into routine service delivery	62%	56%
arly discharge after normal delivery	Not included in round 1	Not included in round 2	No response	Used but not integrated into routine service delivery	59%	56%
	Not included in yound 1	Not included in round 2	×	Used but not integrated into routine service delivery	62%	49%
continuity of labour companion	Not included in round 1					
Continuity of labour companion Enhanced maternal mental health screening and ounselling in maternal health services Using digital platforms for ANC or PNC counseling	Not included in round 1	Not included in round 2	No response	Used but not integrated into routine service delivery Used but not integrated into	47%	42%

In-depth profile: Sexual, reproductive, maternal, newborn, child and adolescent health, continued Mitigation strategies and recovery measures for child and adolescent health services % of countries using strategy (with or without integration) Round 2 **Global comparison** Round 1 Round 3 Round 4 **Regional comparison Communication and information** (May-Sept 2020) (Jan-March 2021) (Nov-Dec 2021) (Nov 2022-Jan 2023) (Round 4) (Round 4) Informing the community where, when and how Used but not integrated into routine service delivery 94% 85% Not included in round 1 Not included in round 2 to access sick and well child services **Used but not integrated into** Enhancing information to caregivers on child care Not included in round 1 85% **76%** Not included in round 2 routine service delivery Providing information on how to manage stress **Used but not integrated into** 64% and sustain nurturing care in households during 64% Not included in round 1 Not included in round 2 X routine service delivery COVID-19 Informing adolescents where and how to access **Used but not integrated into 79**% Not included in round 1 Not included in round 2 68% routine service delivery health services Informing adolescents where and how to get **Used but not integrated into** 64% Not included in round 1 Not included in round 2 **59%** \times routine service delivery support and care in case of violence Informing health workers about the heightened Used but not integrated into routine service delivery risk to children and adolescents of violence, Not included in round 1 Not included in round 2 **67%** 64% including sexual violence Access Enhancing provision of mental health and **Used but not integrated into** 45% psychosocial support to caregivers of children **50**% Not included in round 1 Not included in round 2 routine service delivery and adolescents Scheduling visits for child and/or adolescent **Used but not integrated into** 48% **52%** Not included in round 1 Not included in round 2 X routine service delivery services in advance Enhance integrated outreach for delivery of **Used but not integrated into 73**% vaccinations, growth monitoring, preventive and Not included in round 1 Not included in round 2 X 64% routine service delivery sick child services Offering multi-month prescriptions for children **Used but not integrated into 55**% 48% and adolescents with conditions that require Not included in round 1 Not included in round 2 X routine service delivery chronic care **Alternative or adaptive measures** Using digital platforms for counselling, screening Used but not integrated into routine service delivery 42% and follow-up after illness on matters related to 49% Not included in round 1 Not included in round 2 X child health Establishing hotlines and/or telemedicine for **Used but not integrated into 58% 52%** Not included in round 2 Not included in round 1 X individual counselling of adolescents routine service delivery Engaging community groups and youth networks **Used but not integrated into** to extend the provision of health information and **85**% Not included in round 1 Not included in round 2 64% X routine service delivery services to adolescents

In-depth profile: Nutrition services Mitigation strategies and recovery measures for nutrition services % of countries using strategy (with or without integration) Round 1 Round 2 Round 3 Round 4 **Global comparison Regional comparison Alternative or adaptive measures** (Round 4) (May-Sept 2020) (Jan-March 2021) (Nov-Dec 2021) (Nov 2022-Jan 2023) (Round 4) Providing/prescribing nutrition drugs and supplies **Used but not integrated into 50%** 54% Not included in round 1 Not included in round 2 routine service delivery for multi-month Making use of alternative delivery channels for **Used but not integrated into** 74% **73%** Not included in round 1 Not included in round 2 \times routine service delivery nutrition services Reducing the frequency of routine nutrition **Used but not integrated into 59%** Not included in round 2 \times 40% Not included in round 1 routine service delivery services, including screening for severe wasting Bundling nutrition services with other nutrition or **Used but not integrated into 65**% Not included in round 1 Not included in round 2 **51%** \times routine service delivery health services **Used but not integrated into** Prioritizing key nutrition interventions 53% Not included in round 1 Not included in round 2 **58%** routine service delivery **Used but not integrated into 59%** Task shifting for essential nutrition services Not included in round 1 46% Not included in round 2 \times routine service delivery **Used but not integrated into** 35% Postponing of some nutrition services Not included in round 2 44% Not included in round 1 routine service delivery **In-depth profile: Care for older people** Mitigation strategies and recovery measures for care for older people % of countries using strategy (with or without integration) Round 1 **Regional comparison** Round 2 Round 3 Round 4 **Global comparison Communication and information** (May-Sept 2020) (Jan-March 2021) (Nov-Dec 2021) (Nov 2022-Jan 2023) (Round 4) (Round 4) Inform older people, their households and **Used but not integrated into** 62% 70% caregivers, regarding where, when and how to Not included in round 1 Not included in round 2 routine service delivery access health and LTC services Inform older people, their households and **Used but not integrated into** 86% 86% Not included in round 1 Not included in round 2 routine service delivery caregivers on IPC measures Inform older people, their households and **Used but not integrated into 72%** caregivers on the importance of promoting 80% Not included in round 1 Not included in round 2 routine service delivery physical and mental health Inform older people, their households and their **Used but not integrated into** 38% caregivers, on where and how to report and get 46% Not included in round 1 Not included in round 2 routine service delivery help in the case of elder abuse Inform health workers about the heightened risk **Used but not integrated into** 41% Not included in round 2 46% Not included in round 1 \times routine service delivery of elder abuse Ensure accessible information and different **Used but not integrated into** 34% communication strategies for older people with **50%** Not included in round 2 Not included in round 1 X routine service delivery impairments Establish hotlines for older people and care **Used but not integrated into** 41% givers to provide targeted information for older 47% Not included in round 2 \times Not included in round 1 routine service delivery people Provide accurate accessible information of COVID-**Used but not integrated into** 86% 19 vaccines and access to COVID-19 vaccines 88% Not included in round 2 Not included in round 1 routine service delivery according to national vaccine policies Access % of countries using strategy (with or without integration) Use telemedicine and/or home outreach **Used but not integrated into** 41% proactively to minimize health facility visits and Not included in round 1 Not included in round 2 **65%** \times routine service delivery schedule visits in advance Offer multi-month prescriptions for older adults **Used but not integrated into 79%** Not included in round 2 82% Not included in round 1 \times routine service delivery who have underlying health conditions Establish mechanisms for medication delivery for **Used but not integrated into** 34% **61%** older adults who have underlying health Not included in round 1 Not included in round 2 \times routine service delivery conditions **Used but not integrated into** 24% 40% Facilitate access to rehabilitation services Not included in round 1 Not included in round 2 \times routine service delivery **Alternative or adaptive measures** % of countries using strategy (with or without integration) Engaging community groups and networks to **Used but not integrated into** 66% extend the provision of health information and Not included in round 2 63% \times Not included in round 1 routine service delivery services to older people Introduce (if doesn't exist) psychosocial support **Used but not integrated into** 48% for older people, for those socially isolated and Not included in round 2 56% Not included in round 1 \times routine service delivery with grief and loss For older people who are care dependent, develop an alternative plan in case the primary **Used but not integrated into** 28% 37% Not included in round 1 Not included in round 2 \times caregiver is unavailable, and identify an routine service delivery alternative caregiver and/or alternative facility Provide education and training for caregivers at home and long-term care facilities on IPC **Used but not integrated into** 48% **57%** Not included in round 1 Not included in round 2 \times routine service delivery measures and how to continue providing care Establish and enhance the mechanism for relieving the burden on caregivers, including **Used but not integrated into** 28% 41% Not included in round 1 Not included in round 2 routine service delivery providing psychological support using digital platforms and respite care

% of countries responding yes women No response No No No 15% 11% No response No No No 124% 11% Regional comparison (Round 4) Global comparison (Round 4) (Nov 2022-Jan 2023) Round 4 (Nov 2022-Jan 2023) Round 4) Regional comparison (Round 4) Round 4) Rou	In-depth profile: Immunization					
Round 4) (Round 4) (During the previous 6 months, which of the following routine in	nmunization services have been	en <i>disrupted</i> due to COVID	0-19 vaccination?		
Psychocountries responding yes pung children No response No No No 15% 11% 11% 11% 11% 11% 11% 11% 11% 11%	Facility-based immunization services for:				-	-
No response No No No 15% 11% 11% 11% 11% 11% 11% 11% 11% 11%						
No response No No No 124% 127% 89% outreach immunization services No	Infants/young children	No response	No	No	24%	14%
No response No response No No No 12% S% 21% No 36% 21% No response Ves No 36% 21% No response Ves No 36% 21% No 36% 21% No separate No response No response No response No	School-aged children and adolescents	No response	No	No	15%	11%
the previous 6 months, which of the following routine immunization services have been improved due to COVID-19 vaccination? Round 2 (Jan-March 2021) Round 3 (Nov-Dec 2021) Round 4 (Nov 2022-Jan 2023) Regional comparison (Round 4) (Round 4) Frequency of countries responding yes and third in round 2 (Not included in round 3 No 16% 19% 19% 19% 19% 19% 19% 19% 19% 19% 19	Pregnant women	No response	No	No	24%	11%
the previous 6 months, which of the following routine immunization services have been improved due to COVID-19 vaccination? Round 2 (Jan-March 2021) Round 3 (Nov-Dec 2021) (Nov 2022-Jan 2023) Regional comparison (Round 4) (Round 4) We of countries responding yes to pung children Not included in round 2 Not included in round 3 No 16% 19% Women Not included in round 2 Not included in round 3 No 16% 19% Not included in round 2 Not included in round 3 No 17% Not included in round 2 Not included in round 3 No 17% Not included in round 2 Not included in round 3 No 17% Not included in round 2 Not included in round 3 No 17% Not included in round 2 Not included in round 3 No 17% Not included in round 2 Not included in round 3 No 17% Not included in round 2 Not included in round 3 No 17% Services Round 2 Round 3 Round 4 Regional comparison Global comparison	Adults	No response	No	No	1 2%	8%
Based immunization services for: Round 2 (Jan-March 2021) Round 3 (Nov-Dec 2021) Round 4 (Nov 2022-Jan 2023) Regional comparison (Round 4) Regional comparison (Round 4) We of countries responding yes and get children and adolescents Not included in round 2 Not included in round 3 No 16% Not included in round 2 Not included in round 3 No 16% Not included in round 2 Not included in round 3 No 17% Not included in round 2 Not included in round 3 No 31% No 31% Regional comparison (Round 4) We of countries responding yes Advanced in round 3 No 16% 16% 19% 28% 24% 24% 25% Not included in round 3 No 17% 31% Regional comparison Global comparison (Round 4) Regional comparison Global comparison Global comparison Global comparison Global comparison Global comparison	Routine outreach immunization services	No response	Yes	No	36%	21%
Based immunization services for: Round 2 (Jan-March 2021) Round 3 (Nov-Dec 2021) Round 4 (Nov 2022-Jan 2023) Regional comparison (Round 4) Regional comparison Global comparison Gl	During the previous 6 months, which of the following routine in	munization services have bee	en <i>improved</i> due to COVID	19 vaccination?		
(Jan-March 2021) (Nov-Dec 2021) (Nov 2022-Jan 2023) (Round 4) (Round 4) (Rou					Regional comparison	Global comparison
Not included in round 2 Not included in round 3 No 15% 19% 19% women Not included in round 2 Not included in round 3 No 28% 25% 25% Not included in round 2 Not included in round 3 No 17% 24% outreach immunization services Not included in round 2 Not included in round 3 No 31% 31% 31%	Facility-based immunization services for:				_	-
Not included in round 2 Not included in round 3 No 28% Not included in round 2 Not included in round 3 No 217% Outreach immunization services Not included in round 2 Not included in round 3 No 31% Increased demand for vaccination resources had a negative impact on routine immunization services? Round 2 Round 3 Round 4 Regional comparison Global comparison					% of countries	s responding yes
Not included in round 2 Not included in round 3 No 17% 24% Outreach immunization services Not included in round 2 Not included in round 3 No 31% 31% 31%	nfants/young children	Not included in round 2	Not included in round 3	No	28%	24%
Not included in round 2 Not included in round 3 No 17% 24% Outreach immunization services Not included in round 2 Not included in round 3 No 31% 31% increased demand for vaccination resources had a negative impact on routine immunization services? Round 2 Round 3 Round 4 Regional comparison Global comparison	School-aged children and adolescents	Not included in round 2	Not included in round 3	No	16%	19%
outreach immunization services Not included in round 2 Not included in round 3 No 31% increased demand for vaccination resources had a negative impact on routine immunization services? Round 2 Round 3 Round 4 Regional comparison Global comparison	regnant women	Not included in round 2	Not included in round 3	No	28%	25%
increased demand for vaccination resources had a negative impact on routine immunization services? Round 2 Round 3 Round 4 Regional comparison Global comparison	adults	Not included in round 2	Not included in round 3	No	17%	24%
Round 2 Round 3 Round 4 Regional comparison Global comparison						2424
	Routine outreach immunization services	Not included in round 2	Not included in round 3	No	31%	31%
% of countries responding yes		ntive impact on routine immur Round 2	nization services? Round 3	Round 4	Regional comparison	Global comparison
No recognition and the second		ntive impact on routine immur Round 2	nization services? Round 3	Round 4	Regional comparison (Round 4)	Global comparison (Round 4)
No response No Not applicable 89%	Has the increased demand for vaccination resources had a nega	ntive impact on routine immur Round 2	nization services? Round 3	Round 4	Regional comparison (Round 4)	Global comparison (Round 4)
	Has the increased demand for vaccination resources had a nega	Round 2 (Jan-March 2021) No response	rization services? Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023) Not applicable	Regional comparison (Round 4) % of countries	Global comparison (Round 4) s responding yes 87%
No response Yes Not applicable 33% 20%	Has the increased demand for vaccination resources had a negative for the increased demand for vaccination resources Human resources Needles or syringes	Round 2 (Jan-March 2021) No response No response	rization services? Round 3 (Nov-Dec 2021) No Yes	Round 4 (Nov 2022-Jan 2023) Not applicable Not applicable	Regional comparison (Round 4) % of countries 89% 33%	Global comparison (Round 4) s responding yes 87% 20%
No response Yes Not applicable 33% 20% exed to dispose used syringes/needles No response No Not applicable 33%	Has the increased demand for vaccination resources had a negative formula of the increased demand for vaccination resources. Human resources Needles or syringes Safety boxed to dispose used syringes/needles	Round 2 (Jan-March 2021) No response No response No response	Round 3 (Nov-Dec 2021) No Yes No	Round 4 (Nov 2022-Jan 2023) Not applicable Not applicable Not applicable	Regional comparison (Round 4) % of countries 89% 33% 33%	Global comparison (Round 4) s responding yes 87% 20% 20%
	Routine outreach immunization services	Not included in round 2	Not included in round 3	No	31%	31%
No response No Not applicable 89%	s the increased demand for vaccination resources had a nega	ntive impact on routine immur Round 2 (Jan-March 2021)	nization services? Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4) % of countries	Global comparison (Round 4) s responding yes
	as the increased demand for vaccination resources had a nega	Round 2 (Jan-March 2021) No response	rization services? Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023) Not applicable	Regional comparison (Round 4) % of countries	Global comparison (Round 4) s responding yes 87%
No response Yes Not applicable 33%	as the increased demand for vaccination resources had a nega uman resources eedles or syringes	Round 2 (Jan-March 2021) No response No response	rization services? Round 3 (Nov-Dec 2021) No Yes	Round 4 (Nov 2022-Jan 2023) Not applicable Not applicable	Regional comparison (Round 4) % of countries 89% 33%	Global comparison (Round 4) s responding yes 87% 20%
r syringes	las the increased demand for vaccination resources had a negation resources luman resources leedles or syringes afety boxed to dispose used syringes/needles	Round 2 (Jan-March 2021) No response No response No response	Round 3 (Nov-Dec 2021) No Yes No	Round 4 (Nov 2022-Jan 2023) Not applicable Not applicable Not applicable	Regional comparison (Round 4) % of countries 89% 33% 33%	Global comparison (Round 4) s responding yes 87% 20% 20%
No response No Not applicable 89%	Human resources Routine outreach immunization services Has the increased demand for vaccination resources had a negative for the increased demand for vaccination resources.	ntive impact on routine immur Round 2 (Jan-March 2021)	nization services? Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4) % of countries	Global compa (Round 4 s responding yes
No response Yes Not applicable 33% Xed to dispose used syringes/needles No Not applicable 33% No response No Not applicable 33% Requipment No Not applicable 63%	Has the increased demand for vaccination resources had a nega	No response No response No response No response No response No response	Round 3 (Nov-Dec 2021) No Yes No No	Round 4 (Nov 2022-Jan 2023) Not applicable Not applicable Not applicable Not applicable	Regional comparison (Round 4) % of countries 89% 33% 33% 63%	Global compariso (Round 4) s responding yes 87% 20% 48%
No response Yes Not applicable 33% 20% 20% 20% 20% 20% 20% 20% 20% 20% 20	Has the increased demand for vaccination resources had a negative formula to the increased demand for vaccination resources. Human resources Needles or syringes Safety boxed to dispose used syringes/needles Cold chain equipment	Round 2 (Jan-March 2021) No response No response No response No response No response	Round 3 (Nov-Dec 2021) No Yes No No No No	Round 4 (Nov 2022-Jan 2023) Not applicable Not applicable Not applicable Not applicable Not applicable	Regional comparison (Round 4) % of countries 89% 33% 63% 52%	Global comparison (Round 4) s responding yes 87% 20% 48%
No response Yes Not applicable 33% xed to dispose used syringes/needles No Rot applicable 33% n equipment No response No Not applicable 63% No response No Not applicable 63%	Has the increased demand for vaccination resources had a negation resources had a negation resources Needles or syringes Safety boxed to dispose used syringes/needles Cold chain equipment	No response	Round 3 (Nov-Dec 2021) No Yes No No No No No	Round 4 (Nov 2022-Jan 2023) Not applicable Not applicable Not applicable Not applicable Not applicable Not applicable	Regional comparison (Round 4) % of countries 89% 33% 63% 52%	Global comparison (Round 4) s responding yes 87% 20% 48%
No response Yes Not applicable 33% 20% 20% 20% No response No Not applicable 33% 20% 20% No requipment No response No Not applicable 63% 48% osal of injection wastage No response No Not applicable 52% 42% 100 Not applicable 52% 100 Not applicable 100 Not appli	Has the increased demand for vaccination resources had a negation resources had a negation resources Needles or syringes Safety boxed to dispose used syringes/needles Cold chain equipment	No response	Round 3 (Nov-Dec 2021) No Yes No	Round 4 (Nov 2022-Jan 2023) Not applicable Not applicable	Regional comparison (Round 4) % of countries 89% 33% 63% 52% Jund 4 2-Jan 2023) munization continues as before	Global comparison (Round 4) s responding yes 87% 20% 48%



	Not applicable	No response	No response	90%	59%
bur	Not included in round 2	Not included in round 3	No response	33%	17%
cha	Not included in round 2	Not included in round 3	No response	0%	11%
chi	Not included in round 2	Not included in round 3	No response	11%	11%
chr	Not included in round 2	Not included in round 3	No response	0%	0%
lei	Not included in round 2	Not included in round 3	No response	0%	16%
den	Not included in round 2	Not included in round 3	No response	0%	16%
dra	Not included in round 2	Not included in round 3	No response	56%	33%
ech	Not included in round 2	Not included in round 3	No response	0%	0%
foo	Not included in round 2	Not included in round 3	No response	11%	6%
hag	Not included in round 2	Not included in round 3	No response	0%	0%
har	Not included in round 2	Not included in round 3	No response	0%	0%
lep	Not included in round 2	Not included in round 3	No response	11%	16%
fil	Not included in round 2	Not included in round 3	No response	67%	56%
myc	Not included in round 2	Not included in round 3	No response	11%	6%
onc	Not included in round 2	Not included in round 3	No response	44%	28%
rab	Not included in round 2	Not included in round 3	No response	11%	11%
sca	Not included in round 2	Not included in round 3	No response	0%	6%
sch	Not included in round 2	Not included in round 3	No response	33%	39%
sth	Not included in round 2	Not included in round 3	No response	33%	28%
sna	Not included in round 2	Not included in round 3	No response	0%	0%
tae	Not included in round 2	Not included in round 3	No response	11%	11%
tra	Not included in round 2	Not included in round 3	No response	44%	32%
lev	Not included in round 2	Not included in round 3	No response	0%	0%
yaw	Not included in round 2	Not included in round 3	No response	11%	17%
	cha chi chr lei den dra ech foo hag har lep fil myc onc rab sca sch sth sna tae tra lev	chi Not included in round 2 chr Not included in round 2 lei Not included in round 2 den Not included in round 2 den Not included in round 2 dra Not included in round 2 ech Not included in round 2 foo Not included in round 2 hag Not included in round 2 har Not included in round 2 lep Not included in round 2 fil Not included in round 2 myc Not included in round 2 myc Not included in round 2 myc Not included in round 2 sca Not included in round 2 sca Not included in round 2 sca Not included in round 2 sch Not included in round 2 sch Not included in round 2 sch Not included in round 2 sth Not included in round 2 sth Not included in round 2 tae Not included in round 2 tae Not included in round 2 tra Not included in round 2 lev Not included in round 2	cha chi Not included in round 2 Not included in round 3 chr Not included in round 2 Not included in round 3 lei Not included in round 2 Not included in round 3 lei Not included in round 2 Not included in round 3 dra Not included in round 2 Not included in round 3 dra Not included in round 2 Not included in round 3 ech Not included in round 2 Not included in round 3 hag Not included in round 2 Not included in round 3 har Not included in round 2 Not included in round 3 har Not included in round 2 Not included in round 3 har Not included in round 2 Not included in round 3 lep Not included in round 2 Not included in round 3 fill Not included in round 2 Not included in round 3 myc Not included in round 2 Not included in round 3 myc Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 3 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3 sca Not included in round 2 Not included in round 3	chi Not included in round 2 Not included in round 3 No response chi Not included in round 2 Not included in round 3 No response chr Not included in round 2 Not included in round 3 No response lei Not included in round 2 Not included in round 3 No response den Not included in round 2 Not included in round 3 No response dra Not included in round 2 Not included in round 3 No response ech Not included in round 2 Not included in round 3 No response foo Not included in round 2 Not included in round 3 No response hag Not included in round 2 Not included in round 3 No response har Not included in round 2 Not included in round 3 No response har Not included in round 2 Not included in round 3 No response fil Not included in round 2 Not included in round 3 No response fil Not included in round 2 Not included in round 3 No response myc Not included in round 2 Not included in round 3 No response onc Not included in round 2 Not included in round 3 No response rab Not included in round 2 Not included in round 3 No response rab Not included in round 2 Not included in round 3 No response sca Not included in round 2 Not included in round 3 No response sca Not included in round 2 Not included in round 3 No response sch Not included in round 2 Not included in round 3 No response sch Not included in round 2 Not included in round 3 No response sch Not included in round 2 Not included in round 3 No response tra Not included in round 2 Not included in round 3 No response tra Not included in round 2 Not included in round 3 No response tra Not included in round 2 Not included in round 3 No response	cha Not included in round 2 Not included in round 3 No response 11% O% Chr Not included in round 2 Not included in round 3 No response 0% O%

Infrastructure and activities	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)		
Government staff responsible for NCDs have been reassigned/deployed to COVID-19 response	YES - Some staff partially supporting COVID-19 efforts along with routine NCD activities	No response	No		
ercentage of government funds for NTDs that ave been reassigned to non-NTD services due o COVID-19 response efforts	None or not yet	No response	None or not yet		
Policies and plans	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4)	Global comparison (Round 4)
				% of cou	ntries responding yes
additional funding currently being allocated for ICDs in the government budget for the COVID- 9 response	×	No response	×	10%	19%
Planned NCD government activities that have been postponed				% of cour	ntries responding yes
one	×	No response	✓	61%	63%
nplementation of NCD Surveys	×	No response	No response	62%	58%
ublic screening programs for NCDs	✓	No response	No response	38%	47%
VHO HEARTS technical package	×	No response	No response	31%	28%
lass communication ampaigns	✓	No response	No response	38%	38%
Rehabilitation packages for NCD	No response	No response	No response	23%	16%
Current impact of COVID-19 on the following				% of cour	ntries responding yes
unding for NCD risk factors activities	No response	No response	No response	33%	25%
unding for NCD healthcare activities	No response	No response	No response	14%	13%
funding for NCD surveillance	No response	No response	No response	29%	17%
rioritization of NCD rick factors activities by	No response	No response	No response	16%	18%
rioritization of NCD risk factors activities by ealth authorities					
rioritization of NCD healthcare activities by	No response	No response	No response	13%	11%
·	No response No response	No response	No response No response	13%	11%
rioritization of NCD healthcare activities by ealth authorities rioritization of NCD surveillance / information					
ealth authorities rioritization of NCD healthcare activities by ealth authorities rioritization of NCD surveillance / information ystem tock out of NCD medicines	No response	No response	No response	10%	10%
ealth authorities rioritization of NCD healthcare activities by ealth authorities rioritization of NCD surveillance / information ystem	No response No response	No response No response	No response No response	10%	10%

In-depth profile: Mental, neurological, and substance us	se disorders				
Policies and plans	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4)	Global comparison (Round 4)
				% of count	ries responding yes
Mental health and psychosocial support response part of national COVID-19 response plan	No response	No response	✓	83%	88%
Funded?	No response	No response	No		
Mental health and psychosocial support response part of national COVID-19 recovery plan?	No response	No response	✓	74%	73%
Funded?	Not included in round 2	Not included in round 3	No		
ollowing activities have been implemented as part of the current mental health and p	osychosocial support (MHPSS) re	esponse plan for COVID-19		% of count	ries responding yes
Orient responders to mental health and psychosocial aspects of COVID-19	✓	✓	✓	87%	83%
Ensure inter-sectoral referral pathways are established and contextualized to the situation of limited physical distancing	✓	×	✓	61%	55%
Distribute timely and accessible information on general and MHPSS services, coping strategies and updates	✓	✓	✓	70%	77%
Provide MHPSS to people in COVID treatment centers, isolation and quarantine	√	✓	✓	83%	76%
Protect the mental health and well-being of all responders ensuring that they can access mental health and psychosocial care.	✓	✓	✓	91%	81%
Provide care and address the basic needs and mental health care needs of people with existing MNS conditions induced or exacerbated by COVID-19	✓	✓	✓	65%	65%
Address the specific mental health and neurological needs of older adults, people with disabilities and other vulnerable persons	✓	✓	✓	43%	48%
Targeted Risk communication strategies/ campaigns to address social stigma	✓	✓	✓	70%	61%
Establish opportunities for the bereaved to mourn even from a distance.	✓	×	✓	48%	40%
Integrate response activities into existing services	No response	✓	✓	78%	73%
Ensure that risk of infection for people with mental neurological and substance use disorders in mental health hospitals and long-term care facilities are minimized	✓	✓	✓	65%	56%
Integrate mental health and psychosocial support preparedness in national emergency response plans	Not included in round 2	Not included in round 3	✓	78%	63%
Review of national mental health policies or plans to include preparedness and response to public health emergencies	Not included in round 2	Not included in round 3	×	61%	54%

	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4) % of countries	Global comparison (Round 4) responding yes
ve a functioning multisectoral mental health d psychosocial coordination platform	✓	✓	✓	41%	54%
Following Ministries and bodies are part of the coordination platform					
Ministry of Health	✓	✓	✓	100%	100%
Ministry of Social/Family Affairs	✓	✓	✓	77%	82%
Ministry of Education	×			85%	82%
		~	√		
Ministry of Labour	×	×	√	15 %	38%
Ministry of Finance	V	V	√	15 %	28%
Ministry of Foreign Affairs	×	×	√	23%	18%
United Nations Agencies Governmental entity responsible for	×	✓	✓	54%	57%
substance use	✓	✓	✓	38%	55%
Non-governmental Organizations	×	✓	✓	92%	86%
Service users' representatives	×	×	✓	46%	41%
National professional associations/societies	✓	✓	✓	54%	67%
National disaster management authority	✓	×	✓	23%	42%
/ID-19 response plan includes provisions for vices and supports for people with post- /ID condition, especially mental and rological sequelae of post-COVID condition	No response	No response	Yes and 100 % funded		
VID-19 recovery plan includes provisions for vices and supports for people with post-VID condition, especially mental and urological sequelae of post-COVID condition	No response	No response	Yes and 100 % funded		
	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4)	Global comparison (Round 4)
eople with post COVID MNS conditions managed in the following settings:				% of countries	responding yes
No services yet established	Not included in round 2	Not included in round 3	×	15%	4%
Specialist mental health facilities	Not included in round 2	Not included in round 3	✓	100%	82%
Specialist neurologist facilities	Not included in round 2	Not included in round 3	×	36%	36%
Specialist internal medicine facilities	Not included in round 2	Not included in round 3	✓	36%	24%
Specialist infectious diseases facilities	Not included in round 2	Not included in round 3	×	18%	13%
General outpatient facilities	Not included in round 2	Not included in round 3	✓	82%	76%
rease in service use/demand for post-COVID ntal health assessments	Not included in round 2	Not included in round 3	No increase (less than 5% increase or decrease)		
	Round 2 (Jan-March 2021)	Round 3 (Nov-Dec 2021)	Round 4 (Nov 2022-Jan 2023)	Regional comparison (Round 4)	Global comparison (Round 4)
vernment policies/directives designating access to essential services for ntal, neurological and substance use (MNS) disorders				% of countries	responding yes
Mental health services at stand-alone psychiatric hospitals	No response	No response	No response	4%	2%
Specialized MNS services at general hospitals	No response	No response	No response	4%	1%
Specialized neurology services at health facilities	No response	No response	No response	4%	1%
Specialized services for substance use disorders at health facilities	No response	No response	No response	5%	3%
Community-based services for MNS disorders including in primary care facilities	No response	No response	No response	13%	5%
veillance					

Key informants			
Round 4 survey sections	Key informant	Key informant position	Key informant
Continuity of essential health services module	Theophile Dushime	Chief Technical Advisor	organisation Ministry of Health
		Cilici recillical Advisor	Ministry of Ficaltif
Sexual, reproductive, maternal, newborn, child and adolescent health	Theophile Dushime	Chief Technical Advisor	Ministry of Health
Nutrition	Theophile Dushime	Chief Technical Advisor	Ministry of Health
Immunization	Theophile Dushime	Chief Technical Advisor	Ministry of Health
Human immunodeficiency virus and hepatitis	Theophile Dushime	Chief Technical Advisor	Ministry of Health
Tuberculosis	Theophile Dushime	Chief Technical Advisor	Ministry of Health
Malaria	Theophile Dushime	Chief Technical Advisor	Ministry of Health
Neglected tropical diseases	Theophile Dushime	Chief Technical Advisor	Ministry of Health
Noncommunicable diseases	Theophile Dushime	Chief Technical Advisor	Ministry of Health
Mental health, neurology and substance use disorders	Theophile Dushime	Chief Technical Advisor	Ministry of Health
Care for older people	Theophile Dushime	Technical Dushime	Ministry of Health
Future acute respiratory pandemic preparedness	Theophile Dushime	Chief Technical Advisor	Ministry of Health